Track record · closed signal

Grifols, S.A. (GRFS) — closed signal from September 16, 2025

Partial Published before the outcome was known, scored automatically when the window closed on December 15, 2025 — -9.2% at the close.

Predicted vs. what happened

GRFS price · publication thesis → realized outcomesplit-adjusted

$9.80 – $10.00Entry zone — fair-value band

$9.95Published — price the day we called it

$11.74Target — the price the thesis aimed for

$10.23Peak — highest point inside the window, not a realized return

$9.03Window close — end-of-window price, context only

What happened

Partial

Reached 16% of the predicted growth at its peak, without hitting the target.

At window close

-9.2%

realized, from the publication price to the last close inside the window

Peak gain

+2.9%

peak, from the publication price — not a realized return

S&P 500, same window

+3.4%

SPY over the identical days, dividend-adjusted

Window close

$9.03

last close inside the window, ended December 15, 2025

Peak price

$10.23

peak on October 2, 2025 — not a realized return

Days to target

—

The thesis — published September 16, 2025

Predicted growth

+18%

over the measurement window

Target price

$11.74

the price the thesis aimed for

Entry zone

$9.80 – $10.00

the fair-value band we waited for

Price at publication

$9.95

published September 16, 2025

Confidence

60%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Grifols looks like a value idea that could bounce back after a sharp drop. The price seems unusually beaten down. The company plans to roughly double plasma capacity in Europe around 09-11, which could lift profits. Independent checks suggest the shares look cheap. Treat this as a 3-month rebound plan with clear exits because debt levels raise the risk, and only if execution stays on track.

Primary drivers

Price looks unusually beaten down, which can set up a near-term rebound.
Europe capacity plan around 09-11 aims to roughly double plasma output.
Independent value checks and a noted Buy rating suggest the stock is cheap.
Short-term trade idea with strict exit rules to control downside risk.

How it played out

GRFS: target was not reached

Lyra published GRFS at 9.95 on 2025-09-16 as a short-term rebound idea with 18% expected growth. The thesis pointed to a beaten-down price, a Europe plasma capacity plan around 09-11, independent value checks, a noted Buy rating, and strict exit rules because debt raised the risk.

Inside the window, GRFS peaked at 10.23 on 2025-10-02, a 2.9% gain. That stayed below the 11.74 target. It never got there. By 2025-12-15, the stock ended at 9.03. The thesis missed on the measured price outcome.

What happened during the window

On 2025-11-04, Grifols reported third-quarter revenue of 1,865 million euros, up 9.1%, and said nine-month revenue was 5,542 million euros. The article also said adjusted EBITDA through September was 1,358 million euros, up 11.2%.

Grifols eleva los ingresos un 9,1% y reduce el apalancamiento con la mejora de la generación de caja

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All GRFS signals